VivoSeq
Other

Mccune-Albright Syndrome

3

Pipeline Programs↗

2

Active Trials↗

2

Companies Involved↗

McCune-Albright syndrome is an early-stage landscape with 3 programs across 2 companies. The most active players are Fresenius Kabi Oncology Ltd., AstraZeneca. 1 therapy is approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fresenius Kabi Oncology Ltd.

1 program

Phase 2AstraZeneca logo

AstraZeneca

0 programs

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

80%

Small molecule

4 of 5 classified programs — the dominant modality here.

20%ALL OTHERSMonoclonal antibody120%

Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.

Analysis

Trial Status

5

clinical trials

Completed3 · 60%
Recruiting2 · 40%

Clinical Trials

Trial Activity

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome
Completed·National Institute of Dental and Craniofacial Research (NIDCR)·Phase 3·NCT00017927·10 enrolled
DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD)
Recruiting·—·Phase 4·NCT05966064·82 enrolled
Faslodex in McCune-Albright Syndrome
Completed·AstraZeneca logoAstraZeneca·Phase 2·NCT00278915·30 enrolled
PET Imaging of Phosphodiesterase-4 (PDE4) in Brain and Peripheral Organs of McCune-Albright Syndrome
Completed·National Institute of Mental Health (NIMH)·Phase 1/2·NCT02743377·16 enrolled
Screening and Natural History of Patients With Polyostotic Fibrous Dysplasia and the McCune-Albright Syndrome
Recruiting·National Institute of Dental and Craniofacial Research (NIDCR)·N/A·NCT00001727·500 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)